Detalhe da pesquisa
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38631003
2.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Oncologist
; 29(2): 142-150, 2024 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37589219
3.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-34407342
4.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(9): 1133-1144, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36055304
5.
Relationship between CYP1B1 polymorphisms (c.142C > G, c.355G > T, c.1294C > G) and lung cancer risk in Polish smokers.
Future Oncol
; 14(16): 1569-1577, 2018 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-29938532
6.
Chemotherapy control by breath profile with application of SPME-GC/MS method.
J Sep Sci
; 35(21): 2908-13, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23001965
7.
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 5(1): e183773, 2019 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30347019
8.
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
EBioMedicine
; 25: 50-57, 2017 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-29122619